Friday, July 10, 2026

Drug profile · INN

human igg1 monoclonal antibody specific for human interleukin-1 alpha

human igg1 monoclonal antibody specific for human interleukin-1 alpha (HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH) is an FDA-listed pharmaceutical active ingredient. Associated with XBiotech Germany GmbH.

EMA: refused Antineoplastic and immunomodulating agents (L01) L01
Patents linked 8
Pipeline programs 2
News articles 0
Drug details — human igg1 monoclonal antibody specific for human interleukin-1 alpha
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
8
Programs
2
Data quality
0.89

Quick answer

human igg1 monoclonal antibody specific for human interleukin-1 alpha (HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH) is an FDA-listed pharmaceutical active ingredient. Associated with XBiotech Germany GmbH.

Key facts

INN human igg1 monoclonal antibody specific for human interleukin-1 alpha
Brand HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01

Approval history

Authority Status Date
EMA refused

Pipeline programs

  1. ALXN2220-ATTRCM-301 Phase 3 · Alexion Europe SAS · Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
  2. PAUF-I Phase 2 · Anaxis Pharma · Advanced and/or metastatic pancreatic adenocarcinoma

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)
  1. US 11773157

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11370831

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10577410

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 10214581

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9783598

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9486523

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 9416172

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8679489

    Inhibiting cell migration

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is human igg1 monoclonal antibody specific for human interleukin-1 alpha?

human igg1 monoclonal antibody specific for human interleukin-1 alpha (HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH) is an FDA-listed pharmaceutical active ingredient. Associated with XBiotech Germany GmbH.

What is the brand name for human igg1 monoclonal antibody specific for human interleukin-1 alpha?

HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH is a marketed brand name for human igg1 monoclonal antibody specific for human interleukin-1 alpha. Check FDA Drugs@FDA for the current US label holder and prescribing information.